NAS:BIVV (USA) Also trade in: Germany Mexico

Bioverativ Inc

$ 104.98 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: 11.36 Bil Enterprise Value $: 11.36 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value 0
Net Current Asset Value 0
Tangible Book 0
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength :

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history

Profitability & Growth :

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history

» BIVV's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02 Est.)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BIVV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare HKSE:02269 NAS:JUNO OCSE:GEN NAS:BLUE NAS:JAZZ NAS:ALKS NAS:ALNY NAS:BMRN NAS:SGEN OCSE:NZYM B XBRU:UCB SZSE:002252 NAS:NBIX NAS:BGNE NAS:SAGE NAS:EXEL XKRX:215600 HKSE:01177 NAS:NKTR NAS:IONS
Traded in other countries 50B.Germany
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Ratios

Current vs industry vs history

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history

More Statistics

Revenue (TTM) (Mil) $ 1,168.5
EPS (TTM) $ 3.28
Beta 0
Volatility % 0
52-Week Range $ 48.14 - 105.01
Shares Outstanding (Mil) 108.22

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N